Trade Biodesix, Inc. - BDSX CFD

Biodesix, Inc. Company profile

About Biodesix Inc

Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Company’s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Biodesix Inc revenues increased 20% to $54.5M. Net loss increased 38% to $43.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Sales, marketing, general and administ increase of 49% to $43.6M (expense), Research and development - Balancing v increase of 19% to $12.2M (expense).